yes, possibly
but big pharma is about profit & they are not going to takeover EMS for $XXXXXXXXXX when the product is simply an "improvement" on their current products & production systems
all i am saying is selling Artimist will not be something simple and big pharma will not pay really big dollars to buy Artimist when it provides a small benefit over existing treatments
don't over-dream